| Eligibility |
Inclusion Criteria: Additional screening criteria check may apply for qualification:
- Japanese healthy adult males
- Subjects aged between 18 and 55 years inclusive at the time of informed consent
- Subjects with a full understanding of the nature of this study who have consented in
writing to participate in the study
Exclusion Criteria: Additional screening criteria check may apply for qualification:
- Subjects with or having a history or treatment history of disorders, including
cardiac, hepatic, renal, gastrointestinal, respiratory, neuropsychiatric,
hematopoietic, or endocrine system disorder, who are judged by the investigator (or
subinvestigator) to be unfit for study participation
- Subjects with a history of drug or food allergies, including anaphylaxis or
significant allergic reactions
- Subjects with a body mass index (BMI) of less than 18.5 kg/m^2 or greater than 25
kg/m^2 at the time of screening or Day -1 or those with a body weight of less than 50
kg or greater than 80 kg
- Subjects who have donated blood or from whom blood samples have been collected in a
total amount of 400 mL or more within 12 weeks prior to informed consent, 200 mL or
more within 4 weeks prior to informed consent, or 800 mL or more within 1 year prior
to informed consent
- Subjects who have donated blood component or platelet apheresis within 2 weeks prior
to informed consent
- Subjects with or having a history of drug dependence or alcohol dependence
- Subjects with clinically significant abnormalities on a 12-lead ECG, with a
Fridericia-corrected QT (QTcF) interval of =450 msec, or with clinically significant
abnormalities on an auscultation
- Subjects with a positive result for hepatitis B virus surface (HBs) antigen,
serological test for syphilis, hepatitis C virus (HCV) antibody, or human
immunodeficiency virus (HIV) antigen/antibody at screening
- Subjects with a positive polymerase chain reaction (PCR) test for Coronavirus disease
2019 (COVID-19)
- Subjects with a family history of sudden death
- Subjects who answered "yes" to any of the items of suicide ideation or suicide
attempts in the Columbia Suicide Rating Scale (C-SSRS) assessment in the screening
period
- Subjects who do not agree to practice contraception during the study period
- Subjects who have previously received anti-RGMa antibodies, including this
investigational product
- Subjects who have participated in other clinical studies and received other
investigational products within 12 weeks before informed consent
- Subjects who have used any drug other than the investigational product in the period
within 7 days before the start of investigational product administration or 5 times
the half-life of the drug, whichever is longer
|
